Dateline City:
KENILWORTH, N.J. & CAMBRIDGE, Mass.
Collaboration Combines Mercks Leadership in Immuno-Oncology with Modernas Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities
KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Moderna Therapeutics today announced a strategic collaboration and
license agreement to develop and commercialize novel messenger RNA
(mRNA)-based personalized cancer vaccines.
Language:
English
Contact:
Merck Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879or Moderna Media:Liz Melone, 617-256-6622orInvestors:Maren Winnick, 617-674-5297
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more